Compare SWMR & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWMR | AQST |
|---|---|---|
| Founded | 2023 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.1M | 529.4M |
| IPO Year | 2026 | 2007 |
| Metric | SWMR | AQST |
|---|---|---|
| Price | $9.12 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 668.6K | ★ 2.0M |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $1,267.13 | $14.58 |
| Revenue Next Year | $490.28 | $32.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $8.45 | $2.94 |
| 52 Week High | $83.30 | $7.05 |
| Indicator | SWMR | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 26.22 | 36.51 |
| Support Level | N/A | $3.69 |
| Resistance Level | $38.06 | $4.35 |
| Average True Range (ATR) | 0.91 | 0.24 |
| MACD | 0.45 | -0.05 |
| Stochastic Oscillator | 12.82 | 24.53 |
Swarmer Inc is a provider of autonomous drone swarm software and AI solutions, specializing in vendor-agnostic technologies. It develops software platforms and artificial intelligence systems for defence applications, enabling military organisations to deploy and coordinate large-scale unmanned and autonomous systems. Its offerings include swarm coordination software, multi-domain unmanned systems integration, collaborative autonomy solutions, and command-and-control software for distributed robotic operations. Its key software and AI systems include: i) STYX AI Command & Control System, ii) MINAS Autonomy and Collaboration AI and iii) TRIDENT Embedded Drone Operating System. The company generates revenue through software license sales.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.